| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.062 | 0.06 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.06 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | 0.07 | 0.07 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.07 | 0.07 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.084 | 0.07 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.095 | 0.07 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.055 | 0.07 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.092 | 0.07 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.07 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.057 | 0.07 |